Skip to content

Safety and Efficacy of Three Variants of Canaloplasty With Phacoemulsification to Treat Glaucoma and Cataract

Comparison of Safety and Efficacy of Three Variants of Canaloplasty: Ab-externo, Ab-interno and Minicanaloplasty Combined With Phacoemulsification to Treat Glaucoma and Cataract. A Randomised, Prospective Study.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02908633
Enrollment
90
Registered
2016-09-21
Start date
2016-02-29
Completion date
2019-12-31
Last updated
2016-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Open Angle Glaucoma, Cataract

Keywords

open angle glaucoma, canaloplasty, migs, abic

Brief summary

It is a comparative study of Safety and Efficacy of Three Variants of Canaloplasty: ab-externo, ab-interno and minicanaloplasty. Combined With Phacoemulsification to Treat Glaucoma and Cataract. It is a Randomised, Prospective Study.

Interventions

Sponsors

Military Institute od Medicine National Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* co-existing glaucoma and cataract * glaucoma types: primary open angle glaucoma, * eye with characteristic glaucoma changes (biomicroscopic,visual field) * IOP over 21 mmHg after washout * patients not tolerating antiglaucoma medications, * patients with poor compliance * progression in visual field

Exclusion criteria

* previous surgical glaucoma procedure * previous cataract surgery * BCVA under 0,004 * closed angle glaucoma secondary glaucoma (pseudoexfoliative, pigmentary) * poorly controlled diabetes mellitus * advanced AMD * active inflammatory disease * pregnancy * mental disease or emotional instability general steroid therapy

Design outcomes

Primary

MeasureTime frame
mean IOPchange form baseline at 24 months
Number of antiglaucoma drugschange from baseline at 24 months
intraoperative complicationsat the day of surgery

Secondary

MeasureTime frameDescription
Best-Corrected Visual Acuitychange from baseline at 24 months
% IOP reductionchange at 24 months from baseline
Visual Field changeschange from baseline at 24 monthsMD,
Early and Late postsurgical complicationswithin 24 months

Countries

Poland

Contacts

Primary ContactMarek Rękas, MD, PhD, Professor
rekaspl@gmail.com+48604113659
Backup ContactAleksandra Kicińska, MD
aleksandra.kicinska@gmail.com+48601339376

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026